+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Kolon Life Science Inc (102940) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 38 Pages
  • August 2023
  • GlobalData
  • ID: 5749105
Kolon Life Science Inc (102940) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kolon Life Science Inc (KLS) develops, manufactures, and commercializes active pharmaceutical ingredients, specialty chemicals and pharmaceutical products. Invossa, the company's lead product is the first cell-mediated gene therapy, for treating moderate (Kellgren and Lawrence grade 3) knee osteoarthritis in the US. The company's cell-mediated gene therapies are focused on providing medicine/drugs for treating degenerative diseases. Its pipeline product portfolio includes KLS-2031 for Iumbosacral radiculopathy; and KLS-3021 for solid cancer among others. The business also sells cosmetics, antibacterial paint additives, and water treatment products. The business features production sites in South Korea's Chungju, Eumseong, and Gimcheon. KLS is headquartered in Gangseo-gu, Seoul, South Korea.

Kolon Life Science Inc Key Recent Developments

  • Apr 13, 2022: Juniper Biologics licenses Kolon's gene therapy for knee osteoarthritis

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Kolon Life Science Inc - Key Facts
  • Kolon Life Science Inc - Key Employees
  • Kolon Life Science Inc - Major Products and Services
  • Kolon Life Science Inc - History
  • Kolon Life Science Inc - Company Statement
  • Kolon Life Science Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • Kolon Life Science Inc - Business Description
  • Business Segment: Bio Business
  • Overview
  • Performance
  • Business Segment: Chemical Business
  • Overview
  • Performance
  • Geographical Segment: Asia Pacific
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Korea
  • Performance
  • Geographical Segment: Others
  • Performance
  • R&D Overview
  • Kolon Life Science Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Kolon Life Science Inc - Strengths
  • Kolon Life Science Inc - Weaknesses
  • Kolon Life Science Inc - Opportunities
  • Kolon Life Science Inc - Threats
  • Kolon Life Science Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Kolon Life Science Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 13, 2022: Juniper Biologics licenses Kolon’s gene therapy for knee osteoarthritis
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Kolon Life Science Inc, Key Facts
  • Kolon Life Science Inc, Key Employees
  • Kolon Life Science Inc, Major Products and Services
  • Kolon Life Science Inc, History
  • Kolon Life Science Inc, Key Competitors
  • Kolon Life Science Inc, Ratios based on current share price
  • Kolon Life Science Inc, Annual Ratios
  • Kolon Life Science Inc, Interim Ratios
  • Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Kolon Life Science Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Kolon Life Science Inc, Performance Chart (2018 - 2022)
  • Kolon Life Science Inc, Ratio Charts
  • Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Kolon Life Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Lotte Chemical Corp
  • Dong-A Socio Holdings Co Ltd
  • Hanwha Solutions Corp
  • Shin Poong Pharm Co Ltd
  • Yuhan Corp
  • SK Chemicals Co Ltd
  • Samjin Pharm Co Ltd
  • Jeil Pharmaceutical Co Ltd